The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care

(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treate...

Full description

Bibliographic Details
Main Authors: Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi, Itaru Matsumura
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Life
Subjects:
Online Access:https://www.mdpi.com/2075-1729/10/11/261
id doaj-b14e64cf97994482ac5b295ec0cc808a
record_format Article
spelling doaj-b14e64cf97994482ac5b295ec0cc808a2020-11-25T04:04:22ZengMDPI AGLife2075-17292020-10-011026126110.3390/life10110261The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical CareAsuka Inoue0Yuji Nozaki1Yasuaki Hirooka2Koji Kinoshita3Yasutaka Chiba4Masanori Funauchi5Itaru Matsumura6Department of Rheumatology, Kindai University Nara Hospital, Nara 630-0293, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Rheumatology, Kindai University Nara Hospital, Nara 630-0293, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Clinical Research Center, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, JapanDepartment of Hematology and Rheumatology, Kindai University School of Medicine, Osaka 589-8511, Japan(1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treated with MTX+IGU (<i>n</i> = 35) and those treated with IGU (<i>n</i> = 71). The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Secondary endpoints, such as the clinical response, retention rate, and safety, were evaluated. (3) Results: The DAS28-CRP difference in the changes between the two groups were −0.2. DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (−1.43 and −1.20 from baseline, respectively). The retention rates were 71.4% in the MTX+IGU groups and 59.2% in the IGU groups (<i>p</i> = 0.16). Adverse events were observed in a total of 6 (17.1%) MTX+IGU patients and 20 (28.2%) IGU patients (<i>p</i> = 0.21). (4) Conclusions: IGU therapy may be a useful treatment option for patients who cannot be treated with MTX.https://www.mdpi.com/2075-1729/10/11/261iguratimodmethotrexaterheumatoid arthritisclinical responseretention rate
collection DOAJ
language English
format Article
sources DOAJ
author Asuka Inoue
Yuji Nozaki
Yasuaki Hirooka
Koji Kinoshita
Yasutaka Chiba
Masanori Funauchi
Itaru Matsumura
spellingShingle Asuka Inoue
Yuji Nozaki
Yasuaki Hirooka
Koji Kinoshita
Yasutaka Chiba
Masanori Funauchi
Itaru Matsumura
The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
Life
iguratimod
methotrexate
rheumatoid arthritis
clinical response
retention rate
author_facet Asuka Inoue
Yuji Nozaki
Yasuaki Hirooka
Koji Kinoshita
Yasutaka Chiba
Masanori Funauchi
Itaru Matsumura
author_sort Asuka Inoue
title The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
title_short The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
title_full The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
title_fullStr The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
title_full_unstemmed The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
title_sort effectiveness and retention rate of iguratimod in japanese rheumatoid arthritis patients with/without methotrexate in daily medical care
publisher MDPI AG
series Life
issn 2075-1729
publishDate 2020-10-01
description (1) Background: We evaluated the clinical response of iguratimod (IGU) in patients with rheumatoid arthritis (RA) being treated with or without methotrexate (MTX) over 54 weeks. (2) Methods: 106 patients with RA undergoing IGU were retrospectively observed. RA patients were divided into those treated with MTX+IGU (<i>n</i> = 35) and those treated with IGU (<i>n</i> = 71). The primary endpoint was the clinical response of the Disease Activity Score assessing 28 joints with C-reactive protein (DAS28-CRP) differences in the changes from baseline to 54 weeks between MTX+IGU and IGU groups. Secondary endpoints, such as the clinical response, retention rate, and safety, were evaluated. (3) Results: The DAS28-CRP difference in the changes between the two groups were −0.2. DAS28-CRP were significantly reduced from the baseline in the MTX+IGU and IGU groups (−1.43 and −1.20 from baseline, respectively). The retention rates were 71.4% in the MTX+IGU groups and 59.2% in the IGU groups (<i>p</i> = 0.16). Adverse events were observed in a total of 6 (17.1%) MTX+IGU patients and 20 (28.2%) IGU patients (<i>p</i> = 0.21). (4) Conclusions: IGU therapy may be a useful treatment option for patients who cannot be treated with MTX.
topic iguratimod
methotrexate
rheumatoid arthritis
clinical response
retention rate
url https://www.mdpi.com/2075-1729/10/11/261
work_keys_str_mv AT asukainoue theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yujinozaki theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yasuakihirooka theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT kojikinoshita theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yasutakachiba theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT masanorifunauchi theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT itarumatsumura theeffectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT asukainoue effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yujinozaki effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yasuakihirooka effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT kojikinoshita effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT yasutakachiba effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT masanorifunauchi effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
AT itarumatsumura effectivenessandretentionrateofiguratimodinjapaneserheumatoidarthritispatientswithwithoutmethotrexateindailymedicalcare
_version_ 1724437058890498048